Core Insights - Investors in the Medical - Biomedical and Genetics sector may consider Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY) for potential value opportunities [1] - A strong Zacks Rank combined with a favorable Value grade is essential for identifying great value stocks [2] Company Comparison - Exelixis has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while CSL Limited has a Zacks Rank of 4 (Sell) [3] - Value investors utilize various traditional metrics to identify undervalued companies [3] Valuation Metrics - EXEL has a forward P/E ratio of 14.36, significantly lower than CSLLY's forward P/E of 29.10 [5] - The PEG ratio for EXEL is 0.48, while CSLLY's PEG ratio is 1.98, indicating EXEL's better expected earnings growth relative to its price [5] - EXEL's P/B ratio is 3.54 compared to CSLLY's P/B of 4.96, further supporting EXEL's more attractive valuation [6] Conclusion - EXEL demonstrates stronger estimate revision activity and more favorable valuation metrics than CSLLY, making it a more appealing option for value investors [7]

Core Viewpoint - The article highlights two growth stocks, Shopify and Exelixis, that are trading under $100 and present attractive investment opportunities due to their solid growth prospects and market positions [2][3]. Group 1: Shopify - Shopify aims to establish itself as a long-term player in the e-commerce industry, which has significant growth potential, with e-commerce sales currently accounting for only 16% of U.S. retail sales [4][5]. - The company provides a platform for businesses to create online storefronts, benefiting from high switching costs due to the customization efforts made by merchants [5]. - Shopify's revenue increased by 21% year-over-year to $2 billion, with a gross margin of 51.1%, up from 49.3% in the previous year [6]. - Free cash flow surged by 243% to $333 million, with a free cash flow margin of 16%, compared to 6% in the prior-year quarter [7]. - The company reported net earnings per share (EPS) of $0.13, a significant improvement from a loss of $1.02 per share in the previous year [7]. - Despite a forward price-to-sales ratio of 11.9, which is considered high, the long-term growth prospects justify the premium for growth-oriented investors [8]. Group 2: Exelixis - Exelixis is a mid-cap biotech company focused on oncology, with its leading product, Cabometyx, being the top-prescribed therapy for renal cell carcinoma and approved for other cancers [9][10]. - The company's total revenue grew by 35.6% year-over-year to $637.2 million, with U.S. sales of Cabometyx reaching $437.6 million, an increase of nearly 7% [10]. - Exelixis reported an EPS of $0.77, a significant rise from $0.25 in the previous year, and is pursuing label expansions for Cabometyx in various cancer treatments [11]. - The company is conducting phase 3 studies for a new product, zanzalintinib, targeting colorectal cancer, which has a significant unmet medical need [13]. - Exelixis maintains a strong pipeline and consistent financial growth, distinguishing itself from many peers in the biotech sector that lack marketable products [14].

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, whil ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

In a market dealing with external shocks, value investing is fast gaining popularity. The success of value investors like Warren Buffett underscores this. Buffett and his business partner, Charlie Munger, managed to register more than 19.8% CAGR for Berkshire Hathaway from 1965 through 2023. This compares favorably with a 10.2% rise of the S&P 500 Index during the same period. In this article, we discuss how the price/earnings to growth (PEG) ratio can become an efficient yardstick in picking the best value ...

Exelixis (EXEL) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this drug developer, should get reflected in its stock price. After all, empirical research shows a strong correlation between tren ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve's monetary policy regarding interest rates is neither too restrictive nor too loose. Economic growth may slow down, but not enough to cause an outright recession. That's the camp that some investors are betting on. But it's important to remember that a Goldilocks scenario like this doesn't necessarily mean it's smooth sailing for stocks. You'll still want to look for well-capitalized companies w ...